ZFGN Awaits Data, SLDB Makes Solid Gains, RCKT On Fire, SGEN Snaps Up CASC

Cascadian Therapeutics rose more than 70% after agreeing to be acquired by Seattle Genetics for $10.00 per share in cash, which equates to a total value of approximately $614 million.

from RTT - Biotech http://ift.tt/2GAsn2l
via IFTTT